SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Machaon who wrote (20526)5/11/1998 9:16:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
bob, H&Q has a lot of confidence in 1999 earnings. Their projection of $0.84 is 2-3 years ahead of Bear Stearns and BancAmerica Robertson Stephens earnings projections.



To: Machaon who wrote (20526)5/11/1998 9:33:00 PM
From: squetch  Read Replies (2) | Respond to of 32384
 
Bob, >>Does Wall Street have confidence in Robinson and LGND?<< I was wondering what the elephants will think tomorrow. I see how the acquisition fits in terms of technology. I think some of the other SRGN targets won't overlap w/ LGND targets. Henry, can tell us for sure. squetch



To: Machaon who wrote (20526)5/11/1998 9:43:00 PM
From: bob zagorin  Read Replies (1) | Respond to of 32384
 
someone asked why jim mccamant didn't mention lgnd on cnbc. don't know but here is his rec. on lgnd as of 3/98 as cited on henry's web site.

"Ligand is now filing for FDA approval of its first product, a treatment for KS, and THREE MORE DRUGS WILL BE FILED FOR APPROVAL in the next two years. In all, Ligand has more than 30 products in development, some of which target multibillion-dollar markets. Ligand also has seven attractive partnerships; the latest is a $174 million blockbuster deal with Lilly for treating metabolic diseases. Add it all together and the company is well positioned to be one of the few profitable biotechs in 1999."
McCamant recommends buying up to $16.00."

btw, i'm so happy to see the board focused on dissecting the news and science. this is what made this thread so great before.




To: Machaon who wrote (20526)5/11/1998 9:51:00 PM
From: Andreas Helke  Read Replies (2) | Respond to of 32384
 
I think that going from 9 to 84 cents for 1999 earnings would be a good guess for the Seragen effect. Ligand just barely manages to get profitable with its own compounds and can therefore collect much of the ONTAK revenue as additional profit.

Andreas